24 HR topiramate 25 MG Extended Release Oral Capsule Trokendi
1 INDICATIONS AND USAGE TROKENDI XR ® is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome (LGS) in patients 6 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy TROKENDI XR ® is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older [see Clinical Studies (14.2) ] . 1.2 Adjunctive Therapy Epilepsy TROKENDI XR ® is indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 6 years of age and older [see Clinical Studies (14.3) ] . 1.3 Migraine TROKENDI XR ® is indicated for the preventive treatment of migraine in patients 12 years of age and older [see Clinical Studies (14.4) ] .
Supernus Pharmaceuticals
CAPSULE GREEN SPN 25
SPN 25 CAPSULE GREEN
Related Pills
24 hr trokendi 100 mg extended release capsule
supernus pharmaceuticals
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied TROKENDI XR ® (
TOPIRAMATE) extended-release capsules are available in the following strengths and colors: 25 mg (light green opaque body/yellow opaque cap with black print "SPN" and "25"): bottles of 7 count (NDC-17772-101-70), 30 count (NDC-17772-101-30) and 100 count (NDC-17772-101-01) blister packages of 30-count (NDC-17772-101-15) 50 mg (light green opaque body/orange opaque cap with black print "SPN" and "50"): bottles of 7 count (NDC-17772-102-70), 30 count (NDC-17772-102-30) and 100 count (NDC-17772-102-01) blister packages of 30-count (NDC-17772-102-15) 100 mg (green opaque body/blue opaque cap with black print "SPN" and "100"): bottles of 7 count (NDC-17772-103-70), 30 count (NDC-17772-103-30) and 100 count (NDC-17772-103-01) blister packages of 30-count (NDC-17772-103-15) 200 mg (pink opaque body/blue opaque cap with black print "SPN" and "200"): bottles of 7 count (NDC-17772-104-70), 30 count (NDC-17772-104-30) and 100 count (NDC-17772-104-01) blister packages of 30-count (NDC-17772-104-15) 16.2 Storage and Handling TROKENDI XR ® (
TOPIRAMATE) extended-release capsules should be stored in well closed containers at controlled room temperature [25°C (77°F); excursions 15°C-30°C (59°F-86°F)]. Protect from moisture and light.
More pills like CAPSULE SPN 25